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Abstract
Human lysosomal a-galactosidase predominantly hydrolyzes ceramide trihexoside. A transgenic mouse line,
 .C57BLr6CrSIc–TgN GLA 1951 Rin, highly expressing human a-galactosidase, has been established and investigated
biochemically and immunohistochemically in order to clarify the distribution of the expressed enzyme proteins and to
evaluate it as a donor model of organ transplantation therapy for Fabry disease caused by a genetic defect of
a-galactosidase. In these transgenic mice, about five copies of the transgene were integrated, and a-galactosidase activity
was expressed in liver, kidney, heart, spleen, small intestine, submaxillary gland, skeletal muscle, cerebrum, cerebellum,
bone marrow cells and serum. The enzyme activity was about 22 to 11,080-fold higher than that in non-transgenic mice. In
liver, heart and kidney tissues, which are important organs for transplantation studies, sufficient amounts of a-galactosidase
mRNAs were transcribed, and the expressed enzymes, with molecular weights of 54–60 kDa, are abundant in the liver
 y1 y1 .  y1 y1 .enzyme activity: 53,965 nmol h mg protein and heart 39,906 nmol h mg protein , followed by in the kidney
 y1 y1 .tissue 9177 nmol h mg protein , respectively. An immunohistochemical microscopic study clearly demonstrated the
distribution of the expressed enzyme proteins in kidney and liver tissues. Highly expressed a-galactosidase was detected in
glomerular cells, tubular cells and hepatocytes. These transgenic mice will be useful as a donor model for experimental
organ transplantation, and also it will enable recurrent biopsies and long-term observation. The organ transplantation data on
mice will provide us with important information. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
 .Lysosomal a-galactosidase EC 3.2.1.22 cat-
alyzes the degradation of ceramide trihexoside. The
gene encoding a-galactosidase has the structural or-
ganization and regulatory elements of a housekeeping
gene, and the enzyme protein is expected to be
expressed in many tissues and organs. But the details
of its distribution have not been clarified yet. A
genetic defect of the enzyme causes Fabry disease,
and results in systemic accumulation of the substrate,
especially in the kidneys, heart and vascular endothe-
w xlium 1 . In patients with Fabry disease, a renal
disorder develops in adolescence and determines the
prognoses of patients.
So far, infusions of plasma, leukocytes and puri-
w x w xfied a-galactosidase 2,3 and plasma exchange 4
have been tried as therapies for this disease. But,
unfortunately, stable clinical effects have not been
obtained. Other attempts were made, including trans-
w x w xplantation of kidneys 5 and fetal livers 6 . In the
case of renal transplantation, the early experience was
w xnot favorable 7,8 . However, successful transplanta-
w xtion has been achieved recently 9–11 , and long term
observation is necessary. As to fetal liver transplanta-
tion, only two cases have been reported, but the long
term prognosis is not clear.
We have established transgenic mice carrying hu-
man a-galactosidase in many tissues, bone marrow
cells and serum. In this study, we performed bio-
chemical and immunohistochemical analyses of the
kidney and liver tissues, which are useful organs for
transplantation studies, and succeeded in detecting
the expressed human a-galactosidase immunohisto-
chemically and in clarifying its distribution in these
tissues. These results and further experimental trans-
plantation studies involving the transgenic mice as a
donor will provide us with useful information for the
improvement of organ transplantation in humans.
2. Materials and methods
2.1. Transgenic mice
Transgenic mice carrying human a-galactosidase
cDNA were established in our laboratory, according
w xto the methods described previously 12 . Briefly,
a-galactosidase cDNA was prepared from cultured
 .qlymphoblast poly A RNA by means of the reverse
 . w xtranscription-polymerase chain reaction PCR 13 .
The cDNA encoding human a-galactosidase was in-
serted in the vector, pCXN2 supplied by Dr. J.
. w xMiyazaki, Tohoku University, Japan 14 , and then a
3-kb DNA fragment including the chicken b-actin
promotor and human a-galactosidase cDNA, pro-
duced by NdeI digestion of the construct produced
.by Dr. S. Ishii, Usuki Bioresearch Center, Japan ,
was microinjected into pronuclei of fertilized eggs
from superovulated C57BLr6CrSIc female mice ac-
w xcording to the standard method 15 . Then, the zy-
gotes were implanted into pseudopregnant female
SIc:ICR mice. The transgenic mice were designated
 .as C57BLr6CrSIc–TgN GLA 1951Rin, abbreviated
 .as TgN GLA 1951. Animal experiments were per-
formed according to local institutional guidelines.
2.2. Southern blot analysis
Genomic DNA was extracted from the livers of
transgenic and non-transgenic mice, and then di-
gested with P˝uII. One, two, five or 10 copies 15,
.30, 75 or 150 pg of pCXN2 DNA, which contained
the human a-galactosidase cDNA, were mixed with
non-transgenic mouse genomic DNA before P˝uII
digestion, and used as positive controls. The digested
 .DNA 10 mg was separated by electrophoresis on a
1% agarose gel and then transferred to a nitrocellu-
lose membrane BA85; Schleicher and Schuell, Das-
.sel, Germany . The membrane was hybridized with a
32P-labeled P˝uII fragment of human a-galacto-
 .sidase cDNA cDNAa7-827 as the probe, as de-
w xscribed previously 16 .
2.3. Northern blot analysis
Total RNA was extracted from the liver, kidney
and heart tissues of transgenic and non-transgenic
 .qmice. Poly A RNA was isolated from total RNA
 . using Oligo dT -Latex beads Nippon Roche, Tokyo,
.Japan according to the manufacturer’s method.
 .q  .Poly A RNA 1 mg from each tissue was separated
by electrophoresis on a 1% agarose gel containing
formaldehyde and then blotted onto a nitrocellulose
 .membrane Schleicher and Schuell . The membrane
was hybridized with a 32P-labeled full-length human
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a-galactosidase cDNA as a probe using a DNA label-
 .ing kit Nippon Gene, Tokyo, Japan . After the data
for a-galactosidase mRNA had been obtained, the
membrane was washed and rehybridized with a 32P-
 .labeled human b-actin cDNA Nippon Gene to con-
firm the quality and quantities of samples.
2.4. Enzyme assaying
Homogenates of tissues involving liver, kidney,
heart, spleen, small intestine, submaxillary gland,
skeletal muscle, cerebrum and cerebellum, and bone
marrow cells were centrifuged at 6000=g for 10
min at 48C, and the obtained supernatants were used
as the samples for enzyme assaying. a-Galactosidase
activity was measured with 4-methylumbelliferyl-a-
 .D-galactopyranoside Nacalai Tesque, Kyoto, Japan
w xas the substrate 17 . The amount of protein was
Fig. 1. Southern blot analysis of human a-galactosidase cDNA in
the mouse genome. Some 10-mg aliquots of genomic DNAs from
the livers of transgenic and non-transgenic mice were digested
with P˝uII. The digested DNAs were electrophoresed on a 1%
agarose gel and then transferred to a nitrocellulose membrane.
The membrane was hybridized with a 32P-labeled P˝uII frag-
ment of human a-galactosidase cDNA as a probe. The transgene
was detected as a 0.8-kb band, and several faint non-specific
bands of larger sizes were found. Lane 1, transgenic mouse
genomic DNA; lane 2, non-transgenic mouse genomic DNA;
lanes 3–6, one, two, five and 10 copies 15, 30, 75, and 150 pg,
.respectively of human a-galactosidase cDNA inserted pCXN2
DNAs were mixed with non-transgenic mouse genomic DNA
before P˝uII digestion, and used as positive controls.
Fig. 2. Northern blot analysis of human a-galactosidase mRNA
 .q  .in mouse tissues. Poly A RNA 1 mg was electrophoresed on
a 1% agarose gel containing formaldehyde and then transferred to
 .a nitrocellulose membrane. A the membrane was hybridized
32  .with a P-labeled full length human a-galactosidase cDNA; B
the membrane was rehybridized with a 32P-labeled human b-actin
 .qcDNA. Lanes 1–3, poly A RNAs from a non-transgenic mouse;
 .q  .lanes 4–6, poly A RNAs from TgN GLA 1951. Lanes 1 and
4, liver; lanes 2 and 5, kidney; lanes 3 and 6, heart. The reason
why a doublet band reacting with b-actin cDNA was found for
the heart tissue is not clear. It might be due to the tissue
specificity or the assay conditions with the probe of human
origin, but not RNA degradation.
determined with a Bio-Rad dye-binding assay kit
 .Bio-Rad, Hercules, CA, USA , using bovine serum
albumin as the standard.
2.5. Western blot analysis
The supernatants of tissue homogenates were sub-
jected to SDS-polyacrylamide gel electrophoresis on
a 5–20% gradient gel under reducing conditions ac-
w xcording to the method of Laemmli 18 . The samples
liver, 0.5 mg protein; kidney, 3.2 mg protein; and
heart, 0.7 mg protein; those of the transgenic mice
y1.having a-galactosidase activity of 50 nmol h
were transferred from the SDS–polyacrylamide gel to
 . a polyvinylidene difluoride PVDF membrane Im-
.mobilon; Millipore, Bedford, MA, USA . The mem-
brane was incubated for 1 h with rabbit anti-human
 . w xa-galactosidase antibodies 1:250 dilution 19 , at
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Table 1
a-Galactosidase activity in the tissues of transgenic and non-transgenic mice
y1 y1 .a-Galactosidase activity nmol h mg protein
 .TgN GLA 1951 Non-transgenic mouse
Liver 53,965 18
Kidney 9177 8
Heart 39,906 4
Spleen 11,056 33
Small intestine 9153 38
Submaxillary gland 30,722 22
Skeletal muscle 33,242 3
Cerebrum 1965 25
Cerebellum 611 27
Bone marrow cells 9354 44
a aSerum 22,450 14
a-Galactosidase activity: anmol hy1 mly1.
room temperature. Then the membrane was incubated
with horseradish peroxidase–conjugated donkey
 .anti-rabbit IgG Amersham, Buckinghamshire, UK ,
and the reacted proteins were detected by means of a
 .chemiluminescence detection system Amersham .
The membrane was exposed for 2 min at room
temperature to an X-ray film and then developed.
2.6. Immunohistochemistry
The mouse tissues were stored at y808C until use,
 .and the frozen sections cut at 10 mm were fixed
with 4% paraformaldehyde in phosphate-buffered
 .saline PBS at 48C for 4 h, and then permeated with
1% Triton X-100 in PBS at 48C for 18 h. The
specimens were incubated with PBS containing 5%
 .  .wrv normal goat serum and 1% wrv bovine
serum albumin at 48C for 18 h to block non-specific
binding. Subsequently, they were treated with rabbit
anti-human a-galactosidase antibodies 1:250 dilu-
.tion at 48C for 72 h, and then finally treated with
 .  X.fluorescein isothiocyanate FITC -conjugated F ab 2
goat anti-rabbit IgG Biosource International, Camar-
.illo, CA, USA at 48C for 18 h.
The stained liver and kidney tissues were exam-
ined with a confocal laser scanning imaging system
 .MRC-600; Bio-Rad, Hemel Hempstead, UK at-
tached to a microscope Optiphot 2; Nikon, Tokyo,
.Japan .
Fig. 3. Western blot analysis of human a-galactosidase in mouse
tissues. Extracts of mouse tissues were subjected to SDS-poly-
acrylamide gel electrophoresis, which was performed on a 5–20%
gradient gel under reducing conditions. Then the proteins were
 .electrotransfered to a polyvinylidene difluoride PVDF mem-
brane, and the membrane was immunoblotted with rabbit anti-hu-
man a-galactosidase antibodies. Lanes 1–3, tissue homogenates
from a non-transgenic mouse; lanes 4–6, tissue homogenates
 .  .from TgN GLA 1951. Lanes 1 and 4, liver 0.5 mg protein ;
 . lanes 2 and 5, kidney 3.2 mg protein ; lanes 3 and 6, heart 0.7
.mg protein .
( )R. Kase et al.rBiochimica et Biophysica Acta 1406 1998 260–266264
3. Results
3.1. Southern blot analysis
Southern blotting showed the existence of the
 . transgene as a 0.8-kb band in TgN GLA 1951 Fig.
.1 , and the dose of the transgene integrated was
Fig. 4. Indirect immunofluorescence staining of human a-
galactosidase in mouse kidney tissues. Tissue slices were fixed
with 4% paraformaldehyde in PBS, and then permeated with 1%
Triton X-100 in PBS. The specimens were incubated with rabbit
anti-human a-galactosidase antibodies, and then treated with
 .  X.fluorescein isothiocyanate FITC -conjugated F ab goat anti-2
 .  .  .  .rabbit IgG. A kidney cortex of TgN GLA 1951 =200 ; B
 .  .glomerular region arrow in kidney cortex of TgN GLA 1951
 .  .  .=400 ; C kidney cortex of a non-transgenic mouse =200 .
Fig. 5. Indirect immunofluorescence staining of human a-
galactosidase in mouse liver tissues. The procedure was described
 .in Fig. 4, with liver tissues as samples. A liver tissue of
 .  .  .TgN GLA 1951 =200 ; B liver tissue of a non-transgenic
 .mouse =200 .
roughly estimated from the density of the correspond-
ing band. The results demonstrated that about five
copies of the a-galactosidase cDNA were integrated.
3.2. Northern blot analysis
The results of Northern blotting showed that the
integrated human a-galactosidase cDNA highly tran-
scribed the messages, especially in the heart and
 .liver, followed by in kidney tissue of TgN GLA
 .1951 Fig. 2 .
3.3. Enzyme assay and western blot analysis
The a-galactosidase activity in tissues, bone mar-
row cells and serum is summarized in Table 1. High
enzyme activity was found in these tissues, bone
 .marrow cells and serum of TgN GLA 1951, it being
about 22 to 11,080-fold higher than in non-transgenic
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mice. The high expression of human a-galactosidase
in the transgenic mice was also confirmed by West-
ern blotting, in which the expressed enzymes in liver,
kidney and heart tissues were detected as 54–60 kDa
 .bands Fig. 3 . The amounts of the expressed prod-
ucts were high in liver and heart tissues, followed by
in kidney tissue, which was coincident with the re-
sults of enzyme assaying.
3.4. Immunohistochemistry
The distribution of the expressed human a-
 .galactosidase in kidney and liver tissues of TgN GLA
1951 was investigated immunohistochemically with a
specific antibody by confocal microscopy. Im-
munofluorescence revealed intense expression of hu-
man a-galactosidase in glomerular and tubular cells
 .of kidney tissue Fig. 4 . Strong fluorescence was
also found in hepatocytes of the liver, although the
immunoreactivity was observed not to be ubiquitous
 .Fig. 5 .
4. Discussion
Transgenic mice expressing human a-galacto-
sidase in many tissues, bone marrow cells and serum
were generated, and investigated biochemically and
immunohistochemically. Human a-galactosidase was
highly expressed in liver and heart, followed by in
kidney tissue, which are useful organs for transplanta-
tion studies. The molecular sizes of the expressed
enzymes in these tissues were estimated to be 54–60
kDa. The differences are predicted to be due to the
heterogeneity of sugar chains post-translationally
modified in the tissues. In fact, different molecular
weights of a-galactosidase in human tissues have
 w xbeen reported placenta, 57.7 kDa 20 ; and spleen,
w x.49.8 kDa 21 .
In this study, we successfully demonstrated the
distribution of human a-galactosidase in transgenic
mice immunohistochemically. The expressed a-
galactosidase protein was clearly identified in
glomerular and tubular cells of kidney tissue, and
hepatocytes of liver. The transplanted organs could
potentially cure Fabry disease by providing the miss-
ing enzyme.
Fabry disease represents an irreversible cause of
renal failure requiring renal transplantation to correct
w x w xuremia. Renal 5 and fetal liver 6 transplantation
has been performed, expecting also to provide of the
missing enzyme, a-galactosidase. Recently improved
techniques have facilitated successful renal transplan-
w xtation with a high graft survival rate 9–11 . But there
w xhave been few reports of late graft histology 22 ,
because it is difficult to obtain recurrent biopsied
tissues in human subjects. These transgenic mice
overexpressing human a-galactosidase will be useful
as a donor for transplantation to non-transgenic mice.
It enables recurrent biopsies, long-term observation,
and chase study of a-galactosidase originated from a
transplanted organ in a recipient. Recently, Ohshima
w xet al. 23 established a-galactosidase gene knock-out
mice, and showed that they are useful as a Fabry
disease model. Organ transplantation from the trans-
genic mice to such knock-out mice will especially
provide important information for those in human
subjects.
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